A Study to Compare the Safety and Efficacy of Dysport® and Botox® in Adults With Upper Limb Spasticity.
- 18 décembre 2024 - 1 mn de lecture
This study is aiming to demonstrate the non-inferiority of AbobotulinumtoxinA (aboBoNT-A) versus OnabotulinumtoxinA (onaBoNT-A) as the primary safety endpoint, and the superiority of aboBoNT-A over onaBoNT-A with respect to duration of response as the key secondary efficacy endpoint when used at optimal doses according to approved prescribing information of each product.
18 décembre 2024
1 mn de lecture
Which is the Best Dose of Dysport in Helping With Hip Pain for Children With Cerebral Palsy?
18 décembre 2024
1 mn de lecture
Study to Assess Impact of Dysport Injections Early After Stroke on Upper Limb Spasticity Progression
18 décembre 2024
1 mn de lecture
Efficacy and Safety Study of Botulinum Toxin Type-A (Dysport®) in Continent Female Subjects Suffering From Idiopathic Overactive Bladder
18 décembre 2024
1 mn de lecture
Dysport® Pediatric Lower Limb Spasticity Follow-on Study
18 décembre 2024
1 mn de lecture
Dysport® Adult Lower Limb Spasticity Follow-on Study
18 décembre 2024
1 mn de lecture
Dysport® Pediatric Lower Limb Spasticity Study
18 décembre 2024
1 mn de lecture
Dysport® Adult Lower Limb Spasticity Study
18 décembre 2024
1 mn de lecture
Efficacy and Safety of Botulinum Toxin Type A Haemagglutinin Complex Next Generation (BTX-A-HAC NG) in Glabellar Lines
18 décembre 2024
1 mn de lecture
Efficacy and Safety of Clostridium Botulinum Toxin Type A to Improve Appearance of Moderate to Severe Glabellar Lines
18 décembre 2024
1 mn de lecture